MDMA for autism?

MAPS has begun its clinical trial of MDMA for people with autism.   After previous positive results applying the drug to patients with PTSD,  MAPS is now turning to people on the Autism Spectrum.     Potentially very exciting work.


Neural Cell Adhesion Molecule 2 and synapses

Earlier this year, scientists at the University of New South Wales  reported investigating the Neural Cell Adhesion Molecule 2 (NCAM2), linked to autism, Downs.   The team found that NCAM2 clusters were associated with Calcium-ion signaling and associated molecules.     Now, they report low levels of NCAM2 in the hippocampus of patients with Alzheimer’s, suggesting beta-amyloid toxicity leads to loss of NCAM2, which in turn leads to synapse loss. link